Loading…
Based on limited metadata, Polaroisin International Co., Ltd. received an FDA Warning Letter on January 25, 2018, for an unspecified product category classified as "Other." Without access to the full letter text or specific subject line details, the exact nature of the violations cannot be determined from the available information. The issuing FDA office is also not identified in the metadata provided. Additional documentation would be needed to clarify the specific regulatory concerns and violations cited.